Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • PI Industries plans...

    PI Industries plans foray into pharma sector

    Written by savita thakur thakur Published On 2016-09-12T12:12:04+05:30  |  Updated On 12 Sept 2016 12:12 PM IST
    PI Industries plans foray into pharma sector

    Mumbai : Udaipur-based agrochemicals maker PI Industries is looking to foray into the pharma sector for manufacturing and export of early intermediates.


    "Building on our knowledge base in chemistry, we have also planned to foray into the pharma sector for manufacturing and export of early intermediates. We see synergy at the R&D manufacturing and customer end in this area," the company management said in its annual report.


    The company is already working closely with its global partners, focusing on two to three high-potential molecules for the Indian market under the in-licensing arrangement.


    "We have made an investment to the tune of Rs 321.44 crore in FY16 to set up two new state-of-the-art manufacturing facilities at Jambusar and R&D centre at Udaipur. "The 60,000 square feet R&D center is equipped with best in class infrastructure and would house around 150 research scientists," PI Industries Chairman Salil Singhal told shareholders at the companys annual general meeting (AGM).


    The company said its product development team is working on a rich pipeline of products that are being evaluated and are in different stages of registration and it will continue with its tradition of introducing one-two new products every year.


    "To meet with the requirement of our global customers, combined efforts of our R&D, product development and manufacturing teams resulted in commercialising three new high potential molecules during the year.


    "We follow a strategy of launching two to three high potential molecules every year leading to sustained revenue growth and healthy margins," it added.


    The agrochemicals industry is expected to play a pivotal role in driving food security for India, which is on its way to replace China as the world's most populous country.


    With dwindling land under cultivation and an alarmingly lower portion of that under irrigation, the need to increase farm productivity with efficient use of plant nutrients and protection is pressing.


    Estimates suggest that the country loses more than 30 per cent of its farm produce to pests and weeds, which warrants containment through adequate usage of plant protection chemicals, Singhal said.


    The company performed well in 2015-16 given the backdrop of a slowdown in the global agrochemicals industry.


    Its revenue grew by 8.1 per cent to Rs 2,097 crore, while net profit rose by 28.8 per cent at Rs 313 crore.


    "In terms of order book position, we closed the year with a record high of USD 850 million.


    The robust order book with revenue visibility for coming years will continue to drive our investments towards further strengthening our capabilities," PI Industries Managing Director Mayank Singhal said.

    AGMannual general meetinghigh-potential moleculesMayank SinghalPharma Industrypharma sectorPI IndustriesSalil Singhal
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok